Evidence map›Paper›PMID 41090116›Full record

ReviewRheumatology advances in practice2025

Biologic and targeted synthetic DMARD safety in inflammatory arthritis: British Society for Rheumatology guideline scope.

Stephanie F Ling, Joshua L Bennett, Vanessa J Reid, Saad Ahmed, Mostafa Meshaal Ahmad, Sarah Bennett, Marwan Bukhari, Tom Carver, Mary Chatten, Samantha Cooray and 26 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Rheumatology advances in practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

36 authors.

Stephanie F LingCentre for Musculoskeletal Research, University of Manchester, Manchester, UK.ORCID https://orcid.org/0000-0001-8148-2344
Joshua L BennettPaediatric Rheumatology Department, Great North Children's Hospital, Newcastle-upon-Tyne, UK.
Vanessa J ReidKellgren Centre for Rheumatology, Manchester University NHS Foundation Trust, Manchester, UK.
Saad AhmedDepartment of Rheumatology, Cambridge University Hospital, Cambridge, UK.ORCID https://orcid.org/0000-0001-9829-2758
Mostafa Meshaal AhmadDepartment of Rheumatology, NHS Fife, Kirkcaldy, UK.
Sarah BennettRheumatology Department, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
Marwan BukhariDepartment of Rheumatology, University Hospitals of Morecambe Bay NHS Foundation Trust, Lancaster, UK.ORCID https://orcid.org/0000-0003-4311-5222
Tom CarverExpert by Experience, Wirral, UK.
Mary ChattenDepartment of Paediatric Ophthalmology, Queens Medical Centre, Nottingham, UK.
Samantha CoorayDepartment of Paediatric Rheumatology, Great Ormond Street Hospital, London, UK.
Lucy CraigPaediatric Rheumatology Department, Great North Children's Hospital, Newcastle-upon-Tyne, UK.
Cathy DonaghyDepartment of Rheumatology, Belfast Health and Social Care Trust, Belfast, UK.
James GallowayCentre for Rheumatic Diseases, King's College London, London, UK.ORCID https://orcid.org/0000-0002-1230-2781
Mark GibsonCentre for Rheumatic Diseases, King's College London, London, UK.
Rebecca HeatonDepartment of Rheumatology, Stepping Hill Hospital, Stockport NHS Foundation Trust, Stockport, UK.
Holly HendersonExpert by Experience, Bristol, UK.
Nicola HolroydNorth Baddesley Surgery, Southampton, UK.
Akhila KavirayaniDepartment of Paediatric Rheumatology, Oxford University Hospitals NHS Trust, Oxford, UK.
Alison KentRheumatology Department, Salisbury NHS Foundation Trust, Salisbury, UK.
Mariam MalikRheumatology Department, Hampshire Hospitals NHS Foundation Trust, Basingstoke, UK.
Andrew MelvilleDepartment of Rheumatology, York and Scarborough Teaching Hospitals NHS Foundation Trust, York, UK.
Tanjina NasrinRheumatology Department, Salisbury NHS Foundation Trust, Salisbury, UK.
Adlan Wafi RamliDepartment of Acute Medicine, Royal Liverpool University Hospital, Liverpool, UK.ORCID https://orcid.org/0000-0002-2633-6691
Alan RawlingsExpert by Experience, Stone, UK.
Emily Rose-ParfittDepartment of Rheumatology, North Bristol NHS Trust, Bristol, UK.
Luke SammutDepartment of Rheumatology, Portsmouth Hospitals University NHS Trust, Portsmouth, UK.
Ethan S SenPaediatric Rheumatology Department, Great North Children's Hospital, Newcastle-upon-Tyne, UK.
Demisha VaghelaDepartment of Children's Rheumatology, University Hospitals of Leicester NHS Trust, Leicester, UK.
Angela VintExpert by Experience, Ludlow, UK.
Rosemary WallerRheumatology Department, Great Western NHS Foundation Trust, Swindon, UK.
Emma L WilliamsRheumatology Department, Hampshire Hospitals NHS Foundation Trust, Winchester, UK.
Taryn YoungsteinDepartment of Rheumatology, Imperial College Healthcare NHS Trust, London, UK.
Jean ZhangRheumatology Department, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
Sizheng Steven ZhaoCentre for Musculoskeletal Research, University of Manchester, Manchester, UK.
Christopher HolroydRheumatology Department, University Hospital Southampton NHS Foundation Trust, Southampton, UK.ORCID https://orcid.org/0000-0002-3599-8021
British Society for Rheumatology Guideline Steering Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This guideline will provide up-to-date and evidence-based recommendations for the safe use of biologic and targeted synthetic DMARDs in individuals with inflammatory arthritis (IA) across the life course. Important updates from the 2019 iteration of this guideline will include the incorporation of newer pharmacotherapies (such as Janus kinase inhibitors) and an extension of the target clinical population to cover children and young people with IA. The guideline will be updated and produced in accordance with the British Society for Rheumatology protocol for developing clinical guidelines, updated 2023.

Indexed as

axial spondyloarthritisbiological therapyDMARDguidelineJAK inhibitorjuvenile arthritispsoriatic arthritisRheumatoid arthritissafety

Identifiers

PMID41090116
PMCPMC12517738

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.